Article ID Journal Published Year Pages File Type
9220938 Sleep Medicine 2005 9 Pages PDF
Abstract
The significant improvements in sleep and daytime function were evident in those switched from double-blind placebo to 6 months of open-label eszopiclone therapy and were sustained during the 6 months of open-label treatment for those receiving prior double-blind eszopiclone. During 12 months of nightly treatment, eszopiclone 3 mg was well tolerated; tolerance was not observed.
Related Topics
Life Sciences Neuroscience Neurology
Authors
, , , , ,